145 related articles for article (PubMed ID: 30151905)
1. Oral fluorouracil vs vinorelbine plus cisplatin as adjuvant chemotherapy for stage II-IIIA non-small cell lung cancer: Propensity score-matched and instrumental variable analyses.
Urushiyama H; Jo T; Yasunaga H; Michihata N; Matsui H; Hasegawa W; Takeshima H; Sakamoto Y; Hiraishi Y; Mitani A; Fushimi K; Nagase T; Yamauchi Y
Cancer Med; 2018 Oct; 7(10):4863-4869. PubMed ID: 30151905
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the safety and compliance of 3-week cycles of vinorelbine on days 1 and 8 and cisplatin on day 1 as adjuvant chemotherapy in Japanese patients with completely resected pathological stage IB to IIIA non-small cell lung cancer: a retrospective study.
Shukuya T; Takahashi T; Tamiya A; Ono A; Igawa S; Tsuya A; Nakamura Y; Murakami H; Naito T; Kaira K; Endo M; Yamamoto N
Jpn J Clin Oncol; 2009 Mar; 39(3):158-62. PubMed ID: 19139038
[TBL] [Abstract][Full Text] [Related]
3. Survival data for postoperative adjuvant chemotherapy comprising cisplatin plus vinorelbine after complete resection of non-small cell lung cancer.
Kenmotsu H; Ohde Y; Wakuda K; Nakashima K; Omori S; Ono A; Naito T; Murakami H; Kojima H; Takahashi S; Isaka M; Endo M; Takahashi T
Cancer Chemother Pharmacol; 2017 Sep; 80(3):609-614. PubMed ID: 28761967
[TBL] [Abstract][Full Text] [Related]
4. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
Zhong WZ; Wang Q; Mao WM; Xu ST; Wu L; Shen Y; Liu YY; Chen C; Cheng Y; Xu L; Wang J; Fei K; Li XF; Li J; Huang C; Liu ZD; Xu S; Chen KN; Xu SD; Liu LX; Yu P; Wang BH; Ma HT; Yan HH; Yang XN; Zhou Q; Wu YL;
Lancet Oncol; 2018 Jan; 19(1):139-148. PubMed ID: 29174310
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale).
Gebbia V; Galetta D; Lorusso V; Caruso M; Verderame F; Pezzella G; Borsellino N; Durini E; Valenza R; Agostara B; Colucci G;
Lung Cancer; 2008 Sep; 61(3):369-77. PubMed ID: 18308419
[TBL] [Abstract][Full Text] [Related]
6. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial.
Yue D; Xu S; Wang Q; Li X; Shen Y; Zhao H; Chen C; Mao W; Liu W; Liu J; Zhang L; Ma H; Li Q; Yang Y; Liu Y; Chen H; Wang C
Lancet Respir Med; 2018 Nov; 6(11):863-873. PubMed ID: 30150014
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin and vinorelbine followed by ifosfamide plus epirubicin vs the opposite sequence in advanced unresectable stage III and metastatic stage IV non-small-cell lung cancer: a prospective randomized study of the Southern Italy Oncology Group (GOIM).
Colucci G; Gebbia V; Galetta D; Riccardi F; Cariello S; Gebbia N
Br J Cancer; 1997; 76(11):1509-17. PubMed ID: 9400950
[TBL] [Abstract][Full Text] [Related]
8. Comparison of vinorelbine plus cisplatin and S-1 plus cisplatin in concurrent chemoradiotherapeutic regimens for unresectable stage III non-small cell lung cancer.
Shukuya T; Takahashi T; Harada H; Akamatsu H; Sakaguchi C; Imai H; Ono A; Nakamura Y; Tsuya A; Kenmotsu H; Naito T; Murakami H; Endo M; Takahashi K; Yamamoto N
Anticancer Res; 2012 Feb; 32(2):675-80. PubMed ID: 22287762
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin, gemcitabine, and vinorelbine combination therapy in advanced non-small-cell lung cancer: a phase II randomized study of the Southern Italy Cooperative Oncology Group.
Comella P; Frasci G; Panza N; Manzione L; Lorusso V; Di Rienzo G; Cioffi R; De Cataldis G; Maiorino L; Bilancia D; Nicolella G; Natale M; Carpagnano F; Pacilio C; De Lena M; Bianco A; Comella G
J Clin Oncol; 1999 May; 17(5):1526-34. PubMed ID: 10334540
[TBL] [Abstract][Full Text] [Related]
10. Feasibility of postoperative adjuvant chemotherapy of cisplatin plus vinorelbine for completely resected non-small-cell lung cancer: a retrospective study in Japan.
Kenmotsu H; Ohde Y; Shukuya T; Eida H; Akamatsu H; Ono A; Nakamura Y; Tsuya A; Kaira K; Naito T; Murakami H; Takahashi T; Maniwa T; Isaka M; Endo M; Kondo H; Yamamoto N
Respir Investig; 2012 Dec; 50(4):157-61. PubMed ID: 23199980
[TBL] [Abstract][Full Text] [Related]
11. Hybrid (intravenous and oral) administration of vinorelbine plus cisplatinum followed by oral vinorelbine as first-line therapy of advanced non-small cell lung cancer: a phase II study.
Martoni AA; Melotti B; Sperandi F; Giaquinta S; Piana E; Pavesi L; Da Prada G; Lelli G
Lung Cancer; 2008 Jun; 60(3):387-92. PubMed ID: 18160123
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial.
Douillard JY; Rosell R; De Lena M; Carpagnano F; Ramlau R; Gonzáles-Larriba JL; Grodzki T; Pereira JR; Le Groumellec A; Lorusso V; Clary C; Torres AJ; Dahabreh J; Souquet PJ; Astudillo J; Fournel P; Artal-Cortes A; Jassem J; Koubkova L; His P; Riggi M; Hurteloup P
Lancet Oncol; 2006 Sep; 7(9):719-27. PubMed ID: 16945766
[TBL] [Abstract][Full Text] [Related]
13. First-line cisplatin with docetaxel or vinorelbine in patients with advanced non-small-cell lung cancer: a quality of life directed phase II randomized trial of Gruppo Oncologico Italia Meridionale.
Gebbia V; Lorusso V; Galetta D; Caruso M M; Palomba G; Riccardi F; Borsellino N; Carrozza F; Leo S; Ferraù F; Cinieri S; Mancuso G; Mancarella S; Colucci G
Lung Cancer; 2010 Aug; 69(2):218-24. PubMed ID: 19910076
[TBL] [Abstract][Full Text] [Related]
14. Phase II Trial of Adjuvant Atezolizumab Therapy in Elderly Patients with Completely Resected Stage II/III Non-Small Cell Lung Cancer: RELIANCE Trial.
Matsubara T; Yamaguchi M; Shimokawa M; Okamoto I
Clin Lung Cancer; 2024 May; 25(3):280-283. PubMed ID: 38368174
[TBL] [Abstract][Full Text] [Related]
15. Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial.
Zhong WZ; Wang Q; Mao WM; Xu ST; Wu L; Wei YC; Liu YY; Chen C; Cheng Y; Yin R; Yang F; Ren SX; Li XF; Li J; Huang C; Liu ZD; Xu S; Chen KN; Xu SD; Liu LX; Yu P; Wang BH; Ma HT; Yang JJ; Yan HH; Yang XN; Liu SY; Zhou Q; Wu YL
J Clin Oncol; 2021 Mar; 39(7):713-722. PubMed ID: 33332190
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of adjuvant vinorelbine and cisplatin in Japanese patients with completely resected stage II and III non-small cell lung cancer.
Sonobe M; Okubo K; Teramukai S; Yanagihara K; Sato M; Sato T; Chen F; Sato K; Fujinaga T; Shoji T; Omasa M; Sakai H; Miyahara R; Bando T; Date H
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1199-206. PubMed ID: 25253046
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin, gemcitabine and vinorelbine in locally advanced or metastatic non-small-cell lung cancer: a phase I study.
Frasci G; Panza N; Comella P; Nicolella GP; Natale M; Pacilio C; Gravina A; Caputi V; Botti G; Comella G
Ann Oncol; 1997 Oct; 8(10):1045-8. PubMed ID: 9402180
[TBL] [Abstract][Full Text] [Related]
18. Oral vinorelbine plus cisplatin with concomitant radiotherapy as induction therapy for stage III non-small cell lung cancer: Results of a single-arm prospective cohort study.
Hsu PC; Chang JW; Wang CC; Wu CT; Lin YC; Wang CL; Lin TY; Li SH; Wu YC; Kuo SC; Yang CT; Liu CY; Chen CH
Thorac Cancer; 2019 Aug; 10(8):1683-1691. PubMed ID: 31276309
[TBL] [Abstract][Full Text] [Related]
19. A retrospective comparison of adjuvant chemotherapeutic regimens for non-small cell lung cancer (NSCLC): paclitaxel plus carboplatin versus vinorelbine plus cisplatin.
Chang WJ; Sun JM; Lee JY; Ahn JS; Ahn MJ; Park K
Lung Cancer; 2014 Apr; 84(1):51-5. PubMed ID: 24521819
[TBL] [Abstract][Full Text] [Related]
20. [Combination of cisplatin and vinorelbine as adjuvant chemotherapy in non-small cell lung cancer patients--feasibility assessment of 5 consecutively treated patients].
Hirahara K; Tanaka J; Itoh R; Kuriyama H; Tanaka H; Kagamu H; Yoshizawa H; Gejyo F
Gan To Kagaku Ryoho; 2008 Jan; 35(1):109-11. PubMed ID: 18195537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]